CLEC2D and glioma: Tumoral LLT1 expression has been reported in non-Hodgkin’s lymphomas [18], nodular lymphocyte-predominant Hodgkin lymphomas [29], gliomas [16], prostate cancer [15], triple-negative breast cancer [17], colon cancer [30], lung cancer [31], cutaneous squamous cell carcinomas [32], and in HPV-negative oropharyngeal squamous cell carcinomas [33].